World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00809042
Date of registration: 15/12/2008
Primary sponsor: Shiraz University of Medical Sciences
Public title: Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
Scientific title: The Effect of Combination Therapy of Hydroxyurea With L- Carnitine and Magnesium Chloride on he-Matologic Parameters and Cardiac Function of ß-Thalassemia Intermedia Patients.
Date of first enrolment: June 2007
Target sample size: 120
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00809042
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment  
Countries of recruitment
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

- Beta thalassemia intermedia patients with mean hemoglobin level >= 7gr/dl, need to
blood transfusion with more than 6 months interval or no need to blood transfusion

Exclusion Criteria:

- Hypothyroidism

- Hypoparathyroidism

- Diabetes mellitus

- Hepatitis B and C

- Positive tests for human immunodeficiency virus

- Any cardiac symptoms or receiving drug for cardiac disease

- Presence of other hemoglobinopathies except thalassemia intermedia and pregnant or
lactating womens



Age minimum: 4 Years
Age maximum: 35 Years
Gender: Both
Health Condition(s) or Problem(s) studied
ß-Thalassemia Intermedia
Intervention(s)
Drug: hydroxyurea
Drug: hydroxyurea and magnesium chloride
Drug: hydroxyurea,L-carnitine and magnesium chloride
Drug: L-carnitine and hydroxyurea
Primary Outcome(s)
Hematologic Parameters [Time Frame: monthly]
Secondary Outcome(s)
echocardiographic parameters [Time Frame: 6 months]
Secondary ID(s)
3342
SHaghpanah
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history